Search clinical trials for: LEO 80190 Vehicle

Total 3322 results

LEO Pharma

Completed

LEO 124249 Ointment in the Treatment of Alopecia Areata

Alopecia Areata

United States
LEO Pharma

Completed

A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas

Psoriasis Vulgaris

France
LEO Pharma

Completed

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

Actinic Keratosis

United States
LEO Pharma

Terminated

Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.

Atopic Dermatitis

Germany
LEO Pharma

Completed

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Germany, Denmark
LEO Pharma

Completed

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Australia
LEO Pharma

Completed

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Hand Eczema

Germany
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds

Psoriasis Vulgaris

Croatia, Germany, Poland, Serbia
LEO Pharma

Terminated

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Discoid Lupus Erythematosus

United States, France, Germany, Denmark
LEO Pharma

Completed

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Germany
LEO Pharma

Terminated

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Alopecia Areata

Denmark
LEO Pharma

Completed

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Psoriasis Vulgaris

United States, Canada, Germany, United Kingdom, France, Poland
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis

Inverse Psoriasis

Germany
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)

Chronic Hand Eczema

Belgium, Canada, Denmark, Germany, Netherlands, Poland, Spain
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1)

Chronic Hand Eczema

Canada, France, Germany, Italy, Poland, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Completed

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Frontal Fibrosing Alopecia

United States
LEO Pharma

Completed

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

Psoriasis Vulgaris

United States, United Kingdom, Canada, Germany
LEO Pharma

Completed

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Psoriasis Vulgaris

Japan
LEO Pharma

Terminated

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Actinic Keratosis | Squamous Cell Carcinoma

United States, Spain, Canada, Germany, France, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

France
Neo Medical SA
ConfinisCPM

Active, not recruiting

PMCF Neo Pedicle Screw and Cage Systems

Trauma | Degenerative Disc Disease | Spinal Stenosis | Spondylolisthesis | Spinal Tumor | Pseudoarthrosis of Spine

Germany, Spain
Dong-A ST Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Overactive Bladder

Korea, Republic of
LEO Pharma

Completed

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Healthy

United Kingdom
LEO Pharma

Completed

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

A Vasoconstriction Study With LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects

Skin and Connective Tissue Diseases

Japan
Dong-A ST Co., Ltd.

Completed

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

Overactive Bladder

Korea, Republic of
LEO Pharma

Completed

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
LEO Pharma

Completed

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Actinic Keratosis

United States
Dong-A ST Co., Ltd.

Completed

The Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy Subjects

Healthy

Korea, Republic of
Cairo University

Unknown

Clinical Evaluation of Fracture Resistance and Color Changes of Laminate Veneer With Gull Wing Preparation

Discolored Teeth
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
JW Pharmaceutical
LEO Pharma

Completed

Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria

Cholinergic Urticaria

Germany
LEO Pharma

Completed

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Germany, Poland
LEO Pharma

Completed

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Atopic Dermatitis

United States
LEO Pharma

Completed

A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products

Psoriasis Vulgaris

France
Intravacc B.V.
Novotech (Australia) Pty Limited

Completed

Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers (ITV2002)

COVID-19

Australia
LEO Pharma

Completed

LEO 29102 Single and Multiple Dose Study by Dermal Application

Atopic Dermatitis

United Kingdom
Biofrontera Bioscience GmbH

Recruiting

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Actinic Keratoses

United States

3

Subscribe